Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: health

Graphene, hexagonally arranged carbon atoms in a single layer with superior pliability and high conductivity, could advance flexible electronics according to a Penn State-led international research team. Huanyu “Larry” Cheng, Dorothy Quiggle Career Development Professor in Penn State’s Department of Engineering Science and Mechanics (ESM), heads the collaboration, which recently published two studies that could inform research and development of future motion detection, tactile sensing and health monitoring devices.

Investigating how laser processing affects graphene form and function

Several substances can be converted into carbon to create graphene through . Called laser-induced graphene (LIG), the resulting product can have specific properties determined by the original material. The team tested this process and published their results in SCIENCE CHINA Technological Sciences.

Read more | >

Two senior leaders in the US Food and Drug Administration’s vaccine review office are stepping down, even as the agency works toward high-profile decisions around Covid-19 vaccine approvals, authorizations for younger children and booster shots.

The retirements of Dr. Marion Gruber, director of the Office of Vaccines Research and Review at FDA’s Center for Biologics Evaluation and Research, and Dr. Philip Krause, deputy director of the office, were announced in an internal agency email sent on Tuesday and shared with CNN by the FDA.

In the email, CBER Director Dr. Peter Marks said Gruber will retire on October 31 and Krause is leaving in November. Marks thanked Gruber for her leadership throughout efforts to authorize and approve Covid-19 vaccines, and Krause for serving in a “key role in our interactions to address critical vaccine-related issues with our public health counterparts around the world.”

Read more | >

Why not eradicate disease for everyone?

Zolgensma – which treats spinal muscular atrophy, a rare genetic disease that damages nerve cells, leading to muscle decay – is currently the most expensive drug in the world. A one-time treatment of the life-saving drug for a young child costs US$2.1 million.

While Zolgensma’s exorbitant price is an outlier today, by the end of the decade there’ll be dozens of cell and gene therapies, costing hundreds of thousands to millions of dollars for a single dose. The Food and Drug Administration predicts that by2025it will be approving 10 to 20 cell and gene therapies every year.

I’m a biotechnology and policy expert focused on improving access to cell and gene therapies. While these forthcoming treatments have the potential to save many lives and ease much suffering, health care systems around the world aren’t equipped to handle them. Creative new payment systems will be necessary to ensure everyone has equal access to these therapies.

Read more | >

The study investigated whether electrical therapy, coupled with exercise, would show promise in treating tendon disease or ruptures. It showed that tendon cell function and repair can be controlled through electrical stimulation from an implantable device which is powered by body movement.

Researchers at CÚRAM, the SFI Research Centre for Medical Devices based at NUI Galway, have shown how the simple act of walking can power an implantable stimulator device to speed up treatment of musculoskeletal diseases.

The results of have been published in the prestigious journal Advanced Materials.

The research establishes the engineering foundations for a new range of stimulator devices that enable control of musculoskeletal tissue regeneration to treat tendon damage and disease and sports injuries, without the use of drugs or external stimulation.

Read more | >

Trial also will test pausing immunosuppressive medication to improve antibody response.

The National Institutes of Health has begun a clinical trial to assess the antibody response to an extra dose of an authorized or approved COVID-19 vaccine in people with autoimmune disease who did not respond to an original COVID-19 vaccine regimen. The trial also will investigate whether pausing immunosuppressive therapy for autoimmune disease improves the antibody response to an extra dose of a COVID-19 vaccine in this population. The Phase 2 trial is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, and is being conducted by the NIAID-funded Autoimmunity Centers of Excellence.

“Many people who have an autoimmune disease that requires immunosuppressive therapy have had a poor immune response to the authorized and approved COVID-19 vaccines, placing these individuals at high risk for the disease,” said NIAID Director Anthony S. Fauci, M.D. “We are determined to find ways to elicit a protective immune response to the vaccines in this population. This new study is an important step in that direction.”

Read more | >

Wide Area Networks (WANs), the global backbones and workhorses of today’s internet that connect billions of computers over continents and oceans, are the foundation of modern online services. As COVID-19 has placed a vital reliance on online services, today’s networks are struggling to deliver high bandwidth and availability imposed by emerging workloads related to machine learning, video calls, and health care.

To connect WANs over hundreds of miles, fiber optic cables that transmit data using light are threaded throughout our neighborhoods, made of incredibly thin strands of glass or plastic known as optical fibers. While they’re extremely fast, they’re not always reliable: They can easily break from weather, thunderstorms, accidents, and even animals. These tears can cause severe and expensive damage, resulting in 911 service outages, lost connectivity to the internet, and inability to use smartphone apps.

Scientists from the MIT Computer Science and Artificial Intelligence Laboratory (CSAIL) and from Facebook recently came up with a way to preserve the network when the fiber is down, and to reduce cost. Their system, called ARROW, reconfigures the optical light from a damaged fiber to healthy ones, while using an online algorithm to proactively plan for potential fiber cuts ahead of time, based on real-time internet traffic demands.

Read more | >

The global revenue of the pharmaceutical market is 1.2 trillion dollars. With such capital at stake and with the pace of technological disruption, the pharma industry has to embrace new technologies, therapies, and innovations and put a greater focus on prevention and digital health.

In this video, we take a dive into the five trends of how big pharma will adapt to these changing times:

1. Artificial intelligence for drug research and development.
2. Patient design — DIY medicine movements.
3. In silico trials to bypass in vivo clinical testing.
4. New technologies, such as blockchain, in the supply chain.
5. New drug strategies by big pharma companies.

Get access to exclusive content and express your support for The Medical Futurist by joining our Patreon community: https://www.patreon.com/themedicalfuturist.

Read our magazine for further updates and analyses on the future of healthcare:
https://medicalfuturist.com/magazine.

#pharmaceutics #digitalhealth #pharma

Read more | >

Join us on Patreon!
https://www.patreon.com/MichaelLustgartenPhD

Papers referenced in the video:
Human microbiome: an academic update on human body site specific surveillance and its possible role.
https://pubmed.ncbi.nlm.nih.gov/32524177/

Taxonomic signatures of cause-specific mortality risk in human gut microbiome.
https://pubmed.ncbi.nlm.nih.gov/33976176/

The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication.
https://pubmed.ncbi.nlm.nih.gov/32082260/

Inhibiting antibiotic-resistant Enterobacteriaceae by microbiota-mediated intracellular acidification.
https://pubmed.ncbi.nlm.nih.gov/30563917/

Short chain fatty acids in human large intestine, portal, hepatic and venous blood.
https://pubmed.ncbi.nlm.nih.gov/3678950/

Age-Associated Changes in Gut Microbiota and Dietary Components Related with the Immune System in Adulthood and Old Age: A Cross-Sectional Study.
https://pubmed.ncbi.nlm.nih.gov/31370376/

Read more | >

Mutations are a part of life. Every time a virus replicates, there is a chance that its genetic code won’t be copied accurately. These typos travel inside new virus particles as they leave one body and move on to infect the next. Some of these mutations die out; others survive and circulate widely. Some mutations are harmless; others increase infectivity or allow a virus to better escape the immune system—that’s when public health bodies might deem that strain a variant of concern.

Swaps or deletions of single amino acids can change the shapes of different proteins. Mutations can happen in any of the proteins of SARS-CoV-2, and these may change the virus’s properties. Many of the worrisome mutations are found on the spike protein, as it is the target of antibody treatments and is mimicked by the currently authorized COVID-19 vaccines. Researchers are especially troubled when typos occur in two parts of the spike protein—the N-terminal domain, which is at the beginning of the protein and which some antibodies target, and the receptor-binding domain (RBD), which grabs hold of ACE2 receptors on human cells and starts the process of infection.

To understand how specific mutations affect the structure and function of the spike protein and what those changes mean for treatments and vaccines, C&EN talked to Priyamvada Acharya, Rory Henderson, and Sophie Gobeil at Duke University. With colleagues, these researchers have combined biochemical assays, cryo-electron microscopy, and modeling to show how the mutations seen in the variants of concern work together to change the stability of the spike protein. The spike is a trimer of three identical protein strands folded and interwoven together. Before the virus has infected a cell, the spike takes on two conformations: a down state, in which the RBD is hidden, and an up state, in which the RBD faces out, ready to bind to ACE2. The team found that different mutations can increase binding in different ways. This process, in which similar features are arrived at independently, is called convergent evolution.

SARS-CoV-2 variants are emerging and gaining traction around the world. What does that mean for our vaccines and treatments for COVID-19?

Read more | >

TOKYO, Aug 28 (Reuters) — Two people died after receiving Moderna Inc (MRNA.O) COVID-19 vaccine shots that were among lots later suspended following the discovery of contaminants, Japan’s health ministry said on Saturday.

The men in their 30s died this month within days of receiving their second Moderna doses, the ministry said in a release. Each had a shot from one of three manufacturing lots suspended on Thursday. The causes of death are being investigated.

Read more | >